Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
    • Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
      • 1-Minute Consult
      • Commentary
      • Current Drug Therapy
      • Editorial
      • Guidelines to Practice
      • Interpreting Key Trials
      • Letter to the Editor
      • Review
      • Smart Testing
      • Symptoms to Diagnosis
      • The Clinical Picture
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
  • COVID-19
    • Curbside Consults Overview
    • Pulmonary/ICU
    • Patient Subsets & Specific Organ Involvement
    • Therapies
    • Imaging & Procedures
    • Patients with Underlying Disease
    • Virus Background & Testing
    • Healthcare System Practice
  • Conference Coverage
    • ASH Annual Meeting
    • AHA Sessions 2020
    • IDWeek 2020
    • CHEST 2020
    • ADA 2020
    • ACC 2020
  • Advertise
    • Media Kit
    • Contact
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
    • Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
  • COVID-19
    • Curbside Consults Overview
    • Pulmonary/ICU
    • Patient Subsets & Specific Organ Involvement
    • Therapies
    • Imaging & Procedures
    • Patients with Underlying Disease
    • Virus Background & Testing
    • Healthcare System Practice
  • Conference Coverage
    • ASH Annual Meeting
    • AHA Sessions 2020
    • IDWeek 2020
    • CHEST 2020
    • ADA 2020
    • ACC 2020
  • Advertise
    • Media Kit
    • Contact
Editorial

SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now

Jonathan J. Taliercio, DO, George Thomas, MD, Georges N. Nakhoul, MD, MEd, Tushar J. Vachharajani, MD and Ali Mehdi, MD, MEd
Cleveland Clinic Journal of Medicine January 2021, 88 (1) 59-63; DOI: https://doi.org/10.3949/ccjm.88a.20190
Jonathan J. Taliercio
Program Director, Nephrology and Hypertension Fellowship, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Co-investigator, EMPA-KIDNEY study
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: talierj@ccf.org
George Thomas
Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Principal Investigator, EMPA-KIDNEY study
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georges N. Nakhoul
Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Co-investigator, EMPA-KIDNEY study
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tushar J. Vachharajani
Department of Hypertension and Nephrology, Glickman Urological and Kidney Institute, Cleveland Clinic; Clinical Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Principal Investigator, EMPA-KIDNEY study
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali Mehdi
Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading
PDF extract preview

You do not have access to the full text of this article, the first page of the PDF of this article appears above.

REFERENCES

  1. ↵
    1. Lewis EJ,
    2. Hunsicker LG,
    3. Bain RP,
    4. Rohde RD
    . The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329(20):1456–1462. doi:10.1056/NEJM199311113292004
    OpenUrlCrossRefPubMed
  2. ↵
    1. Lewis EJ,
    2. Hunsicker LG,
    3. Clarke WR,
    4. et al.
    5. Collaborative Study Group
    . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12):851–860. doi:10.1056/NEJMoa011303
    OpenUrlCrossRefPubMed
  3. ↵
    1. Brenner BM,
    2. Cooper ME,
    3. de Zeeuw D,
    4. et al.
    5. RENAAL Study Investigators
    . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12):861–869. doi:10.1056/NEJMoa011161
    OpenUrlCrossRefPubMed
  4. ↵
    1. Tsushima Y,
    2. Lansang MC,
    3. Makin V
    . The role of SGLT-2 inhibitors in managing type 2 diabetes. Cleve Clin J Med 2021; 88(1):47–58. doi:10.3949/ccjm.88a.20088
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. American Diabetes Association
    . 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care 2020; 43(suppl 1):S98–S110. doi:10.2337/dc20-S009
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Garber AJ,
    2. Handelsman Y,
    3. Grunberger G,
    4. et al
    . Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2020 Executive Summary. Endocr Pract 2020; 26(1):107–139. doi:10.4158/CS-2019-0472
    OpenUrlCrossRef
  7. ↵
    1. de Boer I,
    2. Luiza Caramori M,
    3. Chan J,
    4. et al
    . Executive summary of the 2020 KDIGO diabetes management in CKD guideline: evidence-based advances in monitoring and treatment. Kidney Int 2020; 98(4):839–848. doi:10.1016/j.kint.2020.06.024
    OpenUrlCrossRefPubMed
  8. ↵
    1. Wanner C,
    2. Inzucchi SE,
    3. Zinman B
    . Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375(18):1801–1802. doi:10.1056/NEJMc1611290
    OpenUrlCrossRefPubMed
    1. Packer M,
    2. Anker SD,
    3. Butler J,
    4. et al
    . Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020 August 28; NEJMoa2022190. doi:10.1056/NEJMoa2022190
    OpenUrlCrossRef
    1. Neal B,
    2. Perkovic V,
    3. Mahaffey KW,
    4. et al
    . Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7):644–657. doi:10.1056/NEJMoa1611925
    OpenUrlCrossRef
    1. Wiviott W,
    2. Raz I,
    3. Bonaca M,
    4. et al
    . Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380(4):347–357. doi:10.1056/NEJMoa1812389
    OpenUrlCrossRefPubMed
  9. ↵
    1. Perkovic V,
    2. Jardine MJ,
    3. Neal B,
    4. et al
    . Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380(24):2295–2306. doi:10.1056/NEJMoa1811744
    OpenUrlCrossRefPubMed
  10. ↵
    1. Heerspink HJL,
    2. Stefánsson BV,
    3. Correa-Rotter R
    . Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383(15):1436–1446. doi:10.1056/NEJMoa2024816
    OpenUrlCrossRefPubMed
  11. ↵ClinicalTrials.gov. EMPA-KIDNEY (The Study of Heart and Kidney Protection with Empagliflozin). Identifier NCT03594110
  12. ↵
    1. Organ Procurement and Transplantation Network
    . AK OPTN/SRTR 2019 annual data report. https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/
  13. ↵
    1. Bakris GL,
    2. Agarwal R,
    3. Anker SD,
    4. Pitt B,
    5. et al.
    6. for the FIDELIO-DKD Investigators
    . Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020 October 23. doi:10.1056/NEJMoa2025845
    OpenUrlCrossRefPubMed
  14. ↵
    1. Heerspink PH,
    2. Parving H-H,
    3. Andress DL,
    4. et al.
    5. SONAR Committees and Investigators
    . Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 2019; 393(10184):1937–1947. doi:10.1016/S0140-6736(19)30772-X
    OpenUrlCrossRefPubMed

This article requires you to have a ccjm.org account to view the full text. If you already have an account, you may log in below to view this article along with all other CCJM content. If you do not have an account, register here. It’s free!

Log in using your username and password

Forgot your user name or password?
Previous
Back to top

Registration is Now Required for Free Access to CCJM Content

Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.

If you are using a mobile device, click on the settings icon to access the Register link.

In this issue

Cleveland Clinic Journal of Medicine: 88 (1)
Cleveland Clinic Journal of Medicine
Vol. 88, Issue 1
1 Jan 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now
Jonathan J. Taliercio, George Thomas, Georges N. Nakhoul, Tushar J. Vachharajani, Ali Mehdi
Cleveland Clinic Journal of Medicine Jan 2021, 88 (1) 59-63; DOI: 10.3949/ccjm.88a.20190

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now
Jonathan J. Taliercio, George Thomas, Georges N. Nakhoul, Tushar J. Vachharajani, Ali Mehdi
Cleveland Clinic Journal of Medicine Jan 2021, 88 (1) 59-63; DOI: 10.3949/ccjm.88a.20190
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • THE WRITING WAS ON THE WALL
    • INSIGHTS FROM DAPA-CKD
    • MOVING THE GOAL POST: THE 2020 KDIGO GUIDELINE
    • KEY TAKEAWAYS AND PRACTICE POINTERS
    • FUTURE DIRECTIONS
    • A NEW ERA IN THE TREATMENT OF DIABETIC KIDNEY DISEASE
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Trials and tribulations of testosterone therapy in women: Importance of adhering to the evidence
  • Prostate cancer: To screen or not to screen? The question is complicated
Show more Editorial

Similar Articles

Subjects

  • Nephrology
  • Preventive Care
  • Drug Therapy
  • Diabetes
  • Cardiology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit
  • Advertise Contact

Info For

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • Advertisers
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2021 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire